Secondary pulmonary arterial hypertension

to treat or not to treat?

Rade Tomic, Marshall I Hertz

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Purpose of review The purpose of this review is to review recent literature related to mechanisms and treatment options for 'secondary' (i.e., WHO Groups 3 and 5) pulmonary arterial hypertension (PAH). Recent findings Published randomized controlled trials, in general, do not support the use of approved therapies for 'primary' (i.e., WHO Group 1) PAH patients in patients with Group 3 PAH because of the small numbers of patients and inconsistent benefit. Therefore, we currently recommend against the use of these medications for Group 3 PAH. Similarly, there is limited evidence supporting the use of Group 1 PAH medications in Group 5 patients. In most patients with Group 5 PAH, treatment should be directed to the underlying disease. Summary The utility of PAH-specific therapy in WHO Group 3 PAH is unclear because of the small numbers of patients evaluated and inconsistent beneficial effects observed. There is limited evidence supporting the use of PAH medications in Group 5 patients, and they may be harmful in some cases.

Original languageEnglish (US)
Pages (from-to)324-329
Number of pages6
JournalCurrent Opinion in Organ Transplantation
Volume23
Issue number3
DOIs
StatePublished - Jun 1 2018

Fingerprint

Pulmonary Hypertension
Therapeutics
Randomized Controlled Trials

Keywords

  • chronic obstructive pulmonary disease
  • diffuse parenchymal lung disease
  • idiopathic pulmonary fibrosis
  • pulmonary arterial hypertension
  • sarcoidosis

PubMed: MeSH publication types

  • Journal Article
  • Review

Cite this

Secondary pulmonary arterial hypertension : to treat or not to treat? / Tomic, Rade; Hertz, Marshall I.

In: Current Opinion in Organ Transplantation, Vol. 23, No. 3, 01.06.2018, p. 324-329.

Research output: Contribution to journalReview article

@article{9b97ffe6bb3d48ddacb2fa5dda1b2e1e,
title = "Secondary pulmonary arterial hypertension: to treat or not to treat?",
abstract = "Purpose of review The purpose of this review is to review recent literature related to mechanisms and treatment options for 'secondary' (i.e., WHO Groups 3 and 5) pulmonary arterial hypertension (PAH). Recent findings Published randomized controlled trials, in general, do not support the use of approved therapies for 'primary' (i.e., WHO Group 1) PAH patients in patients with Group 3 PAH because of the small numbers of patients and inconsistent benefit. Therefore, we currently recommend against the use of these medications for Group 3 PAH. Similarly, there is limited evidence supporting the use of Group 1 PAH medications in Group 5 patients. In most patients with Group 5 PAH, treatment should be directed to the underlying disease. Summary The utility of PAH-specific therapy in WHO Group 3 PAH is unclear because of the small numbers of patients evaluated and inconsistent beneficial effects observed. There is limited evidence supporting the use of PAH medications in Group 5 patients, and they may be harmful in some cases.",
keywords = "chronic obstructive pulmonary disease, diffuse parenchymal lung disease, idiopathic pulmonary fibrosis, pulmonary arterial hypertension, sarcoidosis",
author = "Rade Tomic and Hertz, {Marshall I}",
year = "2018",
month = "6",
day = "1",
doi = "10.1097/MOT.0000000000000529",
language = "English (US)",
volume = "23",
pages = "324--329",
journal = "Current Opinion in Organ Transplantation",
issn = "1087-2418",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Secondary pulmonary arterial hypertension

T2 - to treat or not to treat?

AU - Tomic, Rade

AU - Hertz, Marshall I

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Purpose of review The purpose of this review is to review recent literature related to mechanisms and treatment options for 'secondary' (i.e., WHO Groups 3 and 5) pulmonary arterial hypertension (PAH). Recent findings Published randomized controlled trials, in general, do not support the use of approved therapies for 'primary' (i.e., WHO Group 1) PAH patients in patients with Group 3 PAH because of the small numbers of patients and inconsistent benefit. Therefore, we currently recommend against the use of these medications for Group 3 PAH. Similarly, there is limited evidence supporting the use of Group 1 PAH medications in Group 5 patients. In most patients with Group 5 PAH, treatment should be directed to the underlying disease. Summary The utility of PAH-specific therapy in WHO Group 3 PAH is unclear because of the small numbers of patients evaluated and inconsistent beneficial effects observed. There is limited evidence supporting the use of PAH medications in Group 5 patients, and they may be harmful in some cases.

AB - Purpose of review The purpose of this review is to review recent literature related to mechanisms and treatment options for 'secondary' (i.e., WHO Groups 3 and 5) pulmonary arterial hypertension (PAH). Recent findings Published randomized controlled trials, in general, do not support the use of approved therapies for 'primary' (i.e., WHO Group 1) PAH patients in patients with Group 3 PAH because of the small numbers of patients and inconsistent benefit. Therefore, we currently recommend against the use of these medications for Group 3 PAH. Similarly, there is limited evidence supporting the use of Group 1 PAH medications in Group 5 patients. In most patients with Group 5 PAH, treatment should be directed to the underlying disease. Summary The utility of PAH-specific therapy in WHO Group 3 PAH is unclear because of the small numbers of patients evaluated and inconsistent beneficial effects observed. There is limited evidence supporting the use of PAH medications in Group 5 patients, and they may be harmful in some cases.

KW - chronic obstructive pulmonary disease

KW - diffuse parenchymal lung disease

KW - idiopathic pulmonary fibrosis

KW - pulmonary arterial hypertension

KW - sarcoidosis

UR - http://www.scopus.com/inward/record.url?scp=85048110754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048110754&partnerID=8YFLogxK

U2 - 10.1097/MOT.0000000000000529

DO - 10.1097/MOT.0000000000000529

M3 - Review article

VL - 23

SP - 324

EP - 329

JO - Current Opinion in Organ Transplantation

JF - Current Opinion in Organ Transplantation

SN - 1087-2418

IS - 3

ER -